Mayo Clinic Laboratories > Elevating accuracy of Alzheimer’s testing

Definitive, evidence-based Alzheimer’s testing

The highest level of detection

The rapid rate of Alzheimer’s disease research and discovery has enabled the development of new therapies that offer hope to millions of patients affected by the life-altering condition. Early, accurate diagnosis is important to access U.S. FDA-approved medications and improve patient care. Lab testing is a powerful tool to attain clear answers that set patients on the right path forward.

View our Alzheimer’s test menu.

Avoid adverse outcomes through superior testing accuracy

For patients affected by Alzheimer’s disease, newly available disease-modifying therapies (DMT) can help manage symptoms, slow disease progression, and improve quality of life. These medications, along with lifestyle modifications and cognitive rehabilitation strategies, are most effective when initiated early in the disease course. The use of advanced laboratory testing to detect brain amyloid pathology provides precise measurements that facilitate access to targeted care.

A changing diagnostic landscape

Research on laboratory testing for Alzheimer’s disease continues to yield information on the role of blood and cerebrospinal fluid biomarkers (CSF) in detecting amyloid pathology. Recognition of these biomarkers has resulted in the development of numerous biomarker evaluations. However, not all tests provide adequate sensitivity and/or specificity to enable diagnostic confidence. Nor do all tests evaluate for the most clinically meaningful biomarkers.

“When you look at how the field has evolved and now that we have disease-modifying therapies available, biomarker testing — good biomarker testing for Alzheimer's disease — will become an essential component of the clinical evaluations of patients with cognitive impairment.

Alicia Algeciras-Schimnich, Ph.D., professor of laboratory medicine and pathology at Mayo Clinic 

Testing optimized for clearer results

Our innovative plasma biomarker test, which evaluates for phosphorylated Tau 217 (p-Tau217), allows for the highest levels of sensitivity, specificity, and overall diagnostic accuracy available. The use of a two-cutpoint approach to results enables 93% overall accuracy and improved diagnostic confidence for more patients. Testing performed in our laboratory using a binary model failed to deliver 90% overall accuracy and resulted in more false positives.


Let us help you dial in your patient’s diagnosis.

Take the next step in accessing the industry’s most accurate, clinically relevant plasma and cerebrospinal fluid biomarker evaluations. Schedule an appointment with one of our team members. 

  1. “Dementia,” World Health Organization. https://www. Reviewed July 31, 2023. Accessed May 2024.
  2. 2024 Alzheimer’s Disease Facts and Figures. Special Report: Mapping a Better Future for Dementia Care Navigation. Alzheimer’s Association.
(BETA) Choose a language to view this content in:
About the translation.